
    
      BR (bendamustine, rituximab) combination is currently accepted as a first-line treatment of
      chronic lymphocytic leukemia (CLL) in patients for whom fludarabine combination chemotherapy
      is not appropriate.

      The objective of this observational study is to provide additional data to confirm the safety
      profile and efficacy of BR for CLL patients treated in routine clinical practice.

      Specific data of interest are: comorbid conditions, CLL characteristics, adverse events,
      reasons for discontinuation BR, overall response rates, complete response rate,
      progression-free survival, overall survival.
    
  